distributor,customer_name,city,country,latitude,longitude,channel,sub_channel,product_name,product_class,quantity,price,sales,month,year,sales_rep_name,manager,sales_team,sales_growth_pct,rolling_avg_3m,lag_1_month,sales_volatility,sales_clean,sales_zscore_price,insight
Gerlach LLC ,Heller-Abernathy Pharmaceutical Limited,Siegburg,Germany,50.8014,7.2044,Hospital,Private,Abatatriptan,Antibiotics,5.0,742.0,3710.0,1,2017,Jimmy Grey,Alisha Cordwell,Charlie,0.0,3710.0,5850.0,11316.07,3710.0,-0.12422635026965027,"Based on the provided sales record, here's my analysis:

**Current Sales Performance:**
The current sales performance is characterized by a modest quantity sold (5.0 units) at an average unit price of €742.00, resulting in total sales of €3,710.00 for January 2017.

**Sales Growth and Volatility:**
There is no sales growth (% = 0.00) compared to the previous period, indicating a flat performance. The rolling average (3M) is also stagnant at €3,710.00, suggesting a consistent but not increasing trend. The sales volatility metric indicates a high level of uncertainty (11,316.07), which may be due to various factors such as market fluctuations or changes in customer behavior.

**Pricing Behavior:**
The price Z-score anomaly (-0.12) suggests that the current pricing is slightly below the expected range, indicating no significant anomalies or deviations from the normal pricing pattern.

**Potential Business Risk or Opportunity:**
Given the stagnant sales growth and high volatility, there may be a risk of losing market share or experiencing reduced revenue if the current trends continue. On the other hand, there is an opportunity to capitalize on the existing customer base and increase sales by improving sales strategies, product offerings, or expanding into new markets.

**Concrete Recommendations:**

1. **Product Line Optimization:** Review the Abatatriptan product line to identify opportunities for improvement, such as bundling with complementary products or offering enhanced features to increase average order value.
2. **Sales Team Empowerment:** Provide Jimmy Grey and his sales team with additional training and resources to effectively engage with customers in Siegburg, Germany, and capitalize on potential upsell/cross-sell opportunities.
3. **Market Analysis and Insights:** Conduct market research to better understand the trends, preferences, and pain points of Heller-Abernathy Pharmaceutical Limited's customer base in Siegburg, Germany, and develop targeted marketing strategies to increase sales.

**What Factors Make Sales Growth and Loss:**
Sales growth and loss are influenced by various factors, including:

1. **Market Trends:** Changes in demand, market shifts, or competitor actions can impact sales.
2. **Product Offerings:** The quality, features, and pricing of products can affect sales performance.
3. **Customer Behavior:** Customer preferences, purchasing habits, and loyalty can influence sales growth or decline.
4. **Sales Strategies:** Effective sales techniques, account management, and relationship building can drive sales growth.

By addressing these factors, Gerlach LLC can improve its sales performance, increase revenue, and strengthen its partnership with Heller-Abernathy Pharmaceutical Limited."
Gerlach LLC ,"Pfannerstill, Upton and Balistreri Pharm",Ilmenau,Germany,50.6872,10.9142,Pharmacy,Institution,Abatatriptan,Antibiotics,10.0,742.0,7420.0,1,2017,Stella Given,Alisha Cordwell,Charlie,1.0,5565.0,3710.0,11316.07,7420.0,-0.11358351330124412,"**Sales Performance Analysis**

Based on the provided sales record, here's an analysis of Pfannerstill, Upton and Balistreri Pharm's (Pfannerstill) performance in 1-2017:

**Current Sales Performance:**
The sales metrics indicate a moderate level of activity. The quantity sold is relatively stable at 10 units, with an average unit price of €742.00, resulting in total sales of €7,420.00.

**Sales Growth and Volatility:**
Pfannerstill's sales growth rate is low at 1.00%, indicating a slow pace of growth. The rolling average for the past three months (3M) stands at €5,565.00, suggesting some consistency in their sales performance. However, the previous month's sales were lower at €3,710.00, which may indicate some seasonality or variability in demand.

**Pricing Behavior:**
The price Z-score indicates a relatively normal pricing behavior with a score of -0.11, which is close to zero. This suggests that the prices charged by Pfannerstill are within the expected range for their product category and market conditions.

**Business Risk or Opportunity:**
Based on these metrics, there appears to be no significant business risk or opportunity that requires immediate attention. However, the low sales growth rate may indicate a need to review and adjust strategies to drive future growth.

**Concrete Recommendations:**

1. **Analyze Sales Data:** Conduct a deeper analysis of sales data to identify trends, seasonality, and patterns in demand to inform future sales strategies.
2. **Product Pricing Review:** Review pricing for Abatatriptan to ensure it remains competitive and aligned with market conditions, considering the low price Z-score as an indicator of normal pricing behavior.
3. **Marketing Initiatives:** Develop targeted marketing initiatives to drive growth, focusing on the Pharmacy/Institution channel in Ilmenau, Germany.

**Factors Affecting Sales Growth and Loss:**
The following factors may impact sales growth or loss:

1. **Seasonality:** Seasonal fluctuations in demand can influence sales performance.
2. **Product Life Cycle:** The product's life cycle stage (e.g., introduction, growth, maturity, decline) can affect sales growth rates.
3. **Market Trends:** Changes in market trends, such as shifting consumer preferences or regulatory changes, can impact sales performance.
4. **Competition:** Intensifying competition from other distributors or manufacturers can lead to lost sales or market share.

By considering these factors and the provided sales metrics, we can better understand Pfannerstill's current performance and inform strategic decisions to drive future growth."
Kozey-Emmerich ,"Spinka, Schowalter and Conn ",Bergheim,Germany,50.9667,6.65,Pharmacy,Retail,Abatatriptan,Antibiotics,900.0,742.0,667800.0,1,2017,Anne Wu,Britanny Bold,Delta,89.0,232493.33,7420.0,377059.65,667800.0,1.78084146707505,"**Sales Analysis: Spinka, Schowalter and Conn**

Current Sales Performance:

The sales performance for Spinka, Schowalter and Conn (SSC) is impressive, with a total sales value of €667,800 in 1-2017. The sales team, Delta, led by Anne Wu, has achieved significant growth, with a sales growth rate of 89%. This indicates that SSC has been successful in expanding its customer base or increasing repeat business.

Sales Growth and Volatility:

The sales growth rate of 89% is substantial, indicating a strong performance. However, the rolling average (3-month) of €232,493.33 suggests that this growth might be due to an anomaly rather than a sustained trend. The previous month's sales of €7,420 are significantly lower than the overall sales for the period. This could indicate a seasonality effect or a one-time event.

Pricing Behavior:

The price Z-score (anomaly) is 1.78, which indicates that the pricing behavior might be abnormal. A high Z-score suggests that the product's price might have increased significantly compared to the industry average or historical data. This could be an opportunity for SSC to capitalize on the premium pricing.

Potential Business Risk or Opportunity:

The high sales growth rate and pricing anomaly suggest that SSC might be well-positioned to capitalize on the market demand for Abatatriptan, an antibiotic product. However, the high price Z-score also indicates a potential risk of losing market share if competitors adjust their prices to remain competitive.

Recommendations:

1. **Monitor Pricing Strategy**: Analyze the pricing strategy and competitor activity to ensure that SSC is not overpricing itself in the market.
2. **Diversify Customer Base**: Consider expanding the customer base by targeting new pharmacies or retail channels to reduce dependence on a single channel.
3. **Optimize Sales Process**: Review the sales process with Delta team to identify opportunities for improvement, such as streamlining order processing or enhancing product knowledge.

Factors Influencing Sales Growth and Loss:

Sales growth and loss can be influenced by various factors, including:

* Product demand and market trends
* Pricing strategy and competitor activity
* Sales team performance and customer relationships
* Seasonality and geographic location
* Regulatory changes and industry developments

In conclusion, SSC has achieved impressive sales growth in 1-2017, driven by a strong performance from the Delta sales team. However, it is essential to monitor pricing behavior and explore opportunities for diversification and process optimization to ensure sustainable growth."
Koss   ,"Harris, Daugherty and Okuneva Pharm",Neuwied,Germany,50.4286,7.4614,Hospital,Government,Abatatriptan,Antibiotics,5.0,742.0,3710.0,1,2017,Thompson Crawford,James Goodwill,Alfa,-0.99,226310.0,667800.0,382346.06,3710.0,-0.12422635026965027,"**Sales Performance Analysis**

Based on the provided sales record, I will analyze Harris, Daugherty and Okuneva Pharm's (HDO) performance in selling Abatatriptan, an Antibiotic product, to Hospital/Government customers in Neuwied, Germany.

**Current Sales Performance:**
The current sales performance is relatively flat with a Sales Growth % of -0.99%, indicating a slight decline in sales compared to the previous period. The Total Sales for January 2017 are €3,710, which is lower than the Previous Month Sales of €6,678,000.

**Sales Growth and Volatility:**
The Rolling Avg (3M) indicates a significant drop in sales over the last three months, from €2,263,100 to €3,710. This volatility suggests that HDO's sales are not stable and may be impacted by external factors such as market fluctuations or changes in customer behavior.

**Pricing Behavior:**
The Price Z-Score (Anomaly) of -0.12 indicates that the price of Abatatriptan is slightly below the average price, which could be an opportunity for HDO to adjust its pricing strategy to reflect changing market conditions.

**Business Risk and Opportunity:**
The negative sales growth and high volatility suggest that HDO may face challenges in maintaining its market share or increasing revenue. However, the abnormal pricing behavior presents an opportunity for HDO to optimize its pricing strategy to improve profitability.

**Actionable Recommendations:**

1. **Conduct Market Analysis**: Analyze the Hospital/Government customer segment to identify any changes in purchasing patterns, trends, or competitor activity that may be impacting sales.
2. **Optimize Pricing Strategy**: Review Abatatriptan's pricing in relation to market conditions and competitors to ensure it is competitive and aligned with business goals.
3. **Enhance Sales Support**: Provide additional training and support to the Alfa sales team to improve their ability to engage with customers, identify opportunities, and develop effective solutions.

**Factors Affecting Sales Growth and Loss:**
The main factors affecting HDO's sales growth and loss are:

* Changes in customer demand and purchasing patterns
* Competition from other distributors or manufacturers
* Market fluctuations and economic conditions
* Availability and pricing of substitutes

By understanding these factors, HDO can develop targeted strategies to mitigate risks and capitalize on opportunities.

**Conclusion:**
HDO's current sales performance is characterized by a decline in sales and high volatility. However, the abnormal pricing behavior presents an opportunity for optimization. By conducting market analysis, optimizing pricing strategy, and enhancing sales support, HDO can improve its performance and achieve business objectives."
Koss   ,Gerlach LLC Pharma Plc,Torgau,Germany,51.5603,13.0056,Hospital,Private,Abatatriptan,Antibiotics,30.0,742.0,22260.0,1,2017,Mary Gerrard,Britanny Bold,Delta,5.0,231256.67,3710.0,378171.37,22260.0,-0.07101216542761954,"Based on the provided sales record, I'll analyze Gerlach LLC Pharma Plc's current sales performance, assess their growth and volatility, evaluate pricing behavior, identify potential risks or opportunities, and offer actionable recommendations to improve sales.

**Current Sales Performance:**
The sales data indicates a moderate level of sales performance. The customer, Gerlach LLC Pharma Plc, has sold 30 units of Abatatriptan (Antibiotics) with a unit price of €742.00, resulting in total sales of €22,260.00.

**Sales Growth and Volatility:**
The sales growth percentage is 5.00%, indicating a stable increase in sales compared to the previous period. The rolling average for the last three months (231256.67) suggests that Gerlach LLC Pharma Plc has experienced steady sales over this period. However, the sales volatility metric (378171.37) indicates high variability in sales, which may be influenced by factors such as market trends or competitor activity.

**Pricing Behavior:**
The price Z-score is -0.07, indicating that the product's pricing behavior is not abnormal compared to industry norms. This suggests that Gerlach LLC Pharma Plc's pricing strategy for Abatatriptan has been consistent with market expectations.

**Potential Business Risk or Opportunity:**
Based on the data, there are no significant red flags indicating a high-risk scenario. However, the high sales volatility could be an opportunity to explore new marketing strategies or product offerings to stabilize sales and capitalize on potential growth.

**Recommendations:**

1. **Expand Distribution Network:** Given the stable sales growth and moderate sales volume, consider expanding the distribution network to reach more hospitals and private customers in Germany. This could involve partnering with local distributors or establishing a direct-to-consumer sales channel.
2. **Product Diversification:** With high sales volatility, it's essential to diversify the product portfolio to reduce dependence on Abatatriptan. Identify complementary products that cater to Gerlach LLC Pharma Plc's customer base and have a similar pricing structure.
3. **Customer Retention Strategies:** As the sales growth percentage is moderate, focus on retaining existing customers through loyalty programs, personalized services, or targeted marketing initiatives.

**Factors Affecting Sales Growth and Loss:**
Sales growth and loss are influenced by various factors, including:

* Market trends and competitor activity
* Product performance and efficacy
* Pricing strategy and customer perceived value
* Customer satisfaction and retention
* Distributor relationships and logistics
* Economic conditions and regulatory changes

In conclusion, Gerlach LLC Pharma Plc's sales performance is stable, with moderate growth and low pricing anomalies. The company can leverage these strengths to explore new opportunities, diversify its product portfolio, and focus on customer retention. By addressing the factors affecting sales growth and loss, Gerlach LLC Pharma Plc can continue to grow and thrive in the German pharmaceutical market."
Koss   ,McDermott Group Pharmaceutical Ltd,Lindau,Germany,47.5458,9.6839,Pharmacy,Institution,Abatatriptan,Antibiotics,100.0,742.0,74200.0,1,2017,Sheila Stones,Britanny Bold,Delta,2.33,33390.0,22260.0,36539.26,74200.0,0.07798755213006653,"**Current Sales Performance:**
The McDermott Group Pharmaceutical Ltd, a customer of Koss, has demonstrated stable sales performance in the first quarter of 2017. The sales team, Delta, led by Sheila Stones, has achieved a total sales value of €74,200, with an average unit price of €742 and quantity sold of 100 units.

**Sales Growth and Volatility:**
The sales growth rate for this period is 2.33%, indicating a moderate increase in sales compared to the previous period. The rolling average sales over the past three months (3M) are €33,390, which suggests that the sales trend has been relatively consistent. However, the sales volatility index of 36,539.26 indicates that there may be some variation in sales from one month to another.

**Pricing Behavior:**
The price Z-score anomaly is 0.08, indicating that the pricing behavior for Abatatriptan is not abnormal. This suggests that the pricing strategy implemented by Koss and the McDermott Group Pharmaceutical Ltd is consistent with industry norms.

**Potential Business Risk or Opportunity:**
Based on the data, there appears to be a potential opportunity for growth in sales volume, as the sales growth rate is moderate (2.33%) and the rolling average sales are stable. However, the high sales volatility index suggests that there may be some uncertainty in future sales performance.

**Concrete Recommendations:**

1. **Sales Incentives:** Offer targeted sales incentives to the Delta team to drive growth in sales volume, focusing on specific product lines like Abatatriptan.
2. **Customer Engagement:** Enhance customer engagement by conducting regular business reviews with the McDermott Group Pharmaceutical Ltd, to identify opportunities for joint growth and address any concerns or issues that may impact future sales performance.
3. **Pricing Optimization:** Conduct a pricing analysis to determine whether there are opportunities to optimize pricing for Abatatriptan in the Lindau market, taking into account competitor pricing strategies and market trends.

**Factors Affecting Sales Growth and Loss:**
The primary factors affecting sales growth and loss include:

* Effective customer engagement and relationship management
* Market trends and competitors' pricing strategies
* Product performance and demand
* Sales team performance and incentivization

By considering these factors, Koss can make data-driven decisions to drive growth and optimize sales performance for Abatatriptan in the Lindau market."
Koss   ,Murray PLC Pharma Plc,Reinbek,Germany,53.5089,10.2483,Hospital,Private,Abatatriptan,Antibiotics,512.0,742.0,379904.0,1,2017,Abigail Thompson,Tracy Banks,Bravo,27.44,155820.0,13356.0,196432.5,379904.0,0.954957318326733,"**Sales Analysis Report: Murray PLC Pharma Plc**

**Current Sales Performance:**
Murray PLC Pharma Plc has experienced a significant increase in sales, with a total of 379,904 euros generated through the distribution channel. The product, Abatatriptan, is an Antibiotic, which indicates strong demand from hospitals and private institutions. This is reflected in the high quantity sold (512 units) at a unit price of 742 euros.

**Sales Growth and Volatility:**
The sales growth rate for Murray PLC Pharma Plc is 27.44%, indicating a substantial increase compared to previous periods. The rolling average sales over the past three months are 155,820 euros, which suggests that this growth is not an anomaly. However, the sales volatility index (196,432.50) indicates that there may be some variability in sales performance.

**Pricing Behavior:**
The price Z-score of 0.95 suggests that the pricing behavior for Abatatriptan is slightly above the average. This could indicate a slight pricing anomaly or an attempt to optimize prices based on market conditions.

**Potential Business Risk or Opportunity:**
Given the strong sales growth and demand for Abatatriptan, there may be opportunities to expand distribution channels or explore new markets. However, the high sales volatility index suggests that there may be some uncertainty in future sales performance. This highlights the importance of monitoring sales trends and adjusting strategies accordingly.

**Actionable Recommendations:**

1. **Increase Sales Force Effectiveness:** With a strong performing sales team (Bravo) led by Abigail Thompson, it is essential to continue investing in their training and development to capitalize on market opportunities.
2. **Pricing Optimization:** Given the slight pricing anomaly detected, consider conducting a thorough price analysis to determine whether adjustments are necessary to maintain competitive positioning or optimize revenue.
3. **Market Expansion:** Explore new markets or distribution channels to further leverage the strong demand for Abatatriptan and reduce dependence on single customer relationships.

**Factors Affecting Sales Growth and Loss:**

1. **Product Demand:** Strong demand for Abatatriptan is driving sales growth, indicating a high level of customer satisfaction and market need.
2. **Market Competition:** The Antibiotic product class may be subject to intense competition, which could impact pricing and sales performance over time.
3. **Economic Conditions:** Economic trends in Germany and the Reinbek region may influence customer purchasing decisions and overall demand for Abatatriptan.

By focusing on these key areas and making data-driven decisions, Murray PLC Pharma Plc can continue to drive growth and optimize its sales strategy for this critical product."
Gerlach LLC ,"Corkery, Trantow and Ferry Pharma Plc",Geesthacht,Germany,53.4381,10.3747,Pharmacy,Institution,Abatatriptan,Antibiotics,7.0,742.0,5194.0,2,2017,Mary Gerrard,Britanny Bold,Delta,-0.99,132818.0,379904.0,214021.67,5194.0,-0.11996921548228781,"Based on the provided sales record, I'll analyze Corkery, Trantow and Ferry Pharma Plc's performance and offer actionable recommendations to improve their sales.

**Current Sales Performance:**
The customer, Corkery, Trantow and Ferry Pharma Plc, has achieved a total sales value of €5,194.00 for the product Abatatriptan in the period 2-2017. The quantity sold is 7.0 units, with an average unit price of €742.00.

**Sales Growth and Volatility:**
The sales growth rate for this customer is -0.99%, indicating a slight decline in sales compared to the previous period. The rolling average (3M) is €132,818.00, suggesting that the customer's sales have been relatively stable over the past three months. However, the sales volatility is high at 214,021.67, implying that there may be some variability in their sales performance.

**Pricing Behavior:**
The price Z-Score (Anomaly) of -0.12 suggests that the pricing behavior for this customer is not significantly abnormal compared to the average market prices.

**Potential Business Risk or Opportunity:**
Given the slight decline in sales growth and high volatility, there may be some business risk associated with Corkery, Trantow and Ferry Pharma Plc's performance. However, the lack of significant pricing anomalies suggests that the company's pricing strategy is not a major concern.

**Recommendations to Improve Sales Performance:**

1. **Review Customer Engagement:** Since sales growth is declining, it may be beneficial to review customer engagement strategies to identify opportunities for improvement. This could include training exercises or workshops focused on product knowledge and customer service.
2. **Analyze Product Mix:** The sales data suggests that Abatatriptan is the primary product sold to Corkery, Trantow and Ferry Pharma Plc. It may be helpful to analyze the product mix to identify opportunities for cross-selling or upselling other relevant products.
3. **Streamline Logistics:** With high sales volatility, there may be an opportunity to optimize logistics and supply chain processes to ensure timely and efficient delivery of products.

**Factors Affecting Sales Growth and Loss:**
Several factors could contribute to the decline in sales growth and high volatility:

* Changes in customer purchasing habits or preferences
* Competition from other distributors or manufacturers
* Economic conditions affecting the pharmaceutical industry in Germany
* Product availability or stock management issues

By understanding these factors, Corkery, Trantow and Ferry Pharma Plc can develop targeted strategies to address specific challenges and improve their sales performance.

**Conclusion:**
In conclusion, while Corkery, Trantow and Ferry Pharma Plc's sales growth is declining, the company's pricing behavior appears relatively stable. By reviewing customer engagement, analyzing product mix, and streamlining logistics, the company may be able to improve its sales performance and mitigate potential business risks."
Gerlach LLC ,Dach PLC ,Deggendorf,Germany,48.8353,12.9644,Hospital,Private,Abatatriptan,Antibiotics,20.0,742.0,14840.0,2,2017,Thompson Crawford,James Goodwill,Alfa,1.86,133312.67,5194.0,213608.81,14840.0,-0.09229783936443182,"**Analysis: Dach PLC's Sales Performance (Q2 2017)**

**Current Sales Performance:** The sales record indicates that Gerlach LLC, as the distributor of Abatatriptan to Dach PLC, has achieved a total sales figure of €14,840 in Q2 2017. The product sold is Antibiotics, specifically Abatatriptan, which falls under the Hospital/Private channel.

**Sales Growth and Volatility:** The Sales Growth percentage stands at 1.86%, indicating a moderate increase in sales compared to previous periods. However, the Rolling Average (3M) sales figure of €133,312.67 suggests that sales may have been high in preceding months, which could imply a slight decline in Q2 2017. Sales Volatility, measured by the standard deviation, is at 213,608.81, indicating that sales can be quite variable.

**Pricing Behavior:** The Price Z-Score (Anomaly) of -0.09 suggests that the price of Abatatriptan is relatively stable and not significantly different from the average market price.

**Potential Business Risk or Opportunity:**

* Sales growth is moderate, which might indicate a stable market share for Gerlach LLC.
* High sales volatility could be a concern if not managed properly.
* Pricing behavior seems to be normal, reducing the risk of pricing-related issues.

**Concrete Recommendations:**

1. **Focus on Customer Retention:** With a moderate sales growth rate, it's essential to maintain and grow existing customer relationships with Dach PLC to ensure continued sales momentum.
2. **Analyze Sales Volatility:** Identify factors contributing to high sales volatility and develop strategies to mitigate these fluctuations, such as inventory management or supply chain optimization.
3. **Pricing Strategy Review:** While pricing behavior appears stable, regularly review market trends and competitor prices to ensure Abatatriptan remains competitively priced.

**What Factors Contribute to Sales Growth and Loss?**

* Customer relationships: Strong ties with Dach PLC can lead to increased sales, while poor relationships might result in decreased sales.
* Market conditions: Changes in the Antibiotics market, such as competition or regulatory shifts, can impact sales growth or loss.
* Product performance: The effectiveness of Abatatriptan and its perceived value by customers can influence sales performance.

By analyzing these factors and implementing targeted strategies, Gerlach LLC can optimize their relationship with Dach PLC and navigate the Antibiotics market to drive future sales growth."
Gerlach LLC ,"Gleichner, Bahringer and Morar Pharmaceutical Limited",Freising,Germany,48.4028,11.7489,Pharmacy,Institution,Abatatriptan,Antibiotics,180.0,742.0,133560.0,2,2017,Thompson Crawford,James Goodwill,Alfa,8.0,51198.0,14840.0,71490.46,133560.0,0.2482729436245649,"Based on the sales record, I'll analyze the current sales performance and provide recommendations to improve it.

**Current Sales Performance:**
The sales performance for Gleichner, Bahringer and Morar Pharmaceutical Limited in 2-2017 is satisfactory. The company has sold 180 units of Abatatriptan, a popular antibiotic product, with a total revenue of €133,560 (based on the unit price of €742). This represents an impressive sales growth of 8% compared to the previous period.

**Sales Growth and Volatility:**
The sales growth rate of 8% indicates a moderate increase in demand for Abatatriptan. However, the sales volatility, which is measured by the standard deviation of monthly sales (71490.46), suggests that there might be some fluctuations in demand over time. This could be attributed to factors such as changes in patient needs, competitor activity, or marketing efforts.

**Pricing Behavior:**
The price Z-Score (Anomaly) of 0.25 indicates that the pricing behavior is within a normal range. There are no significant anomalies or outliers that would suggest pricing issues or competitive concerns.

**Potential Business Risk or Opportunity:**
Based on this sales record, there appears to be an opportunity for further growth in demand for Abatatriptan. The moderate sales growth and relatively low volatility suggest that the product is well-established and has a stable customer base. This could be an opportunity to explore new marketing strategies or expand into adjacent markets.

**Concrete Recommendations:**

1. **Marketing Efforts:** Develop targeted marketing campaigns to increase awareness about Abatatriptan's benefits and encourage more prescribers and patients to consider the product.
2. **Sales Optimization:** Analyze sales data to identify patterns and trends, then optimize the sales team's approach to maximize coverage and conversion rates.
3. **Customer Insights:** Conduct customer surveys or focus groups to gain insights into their needs, preferences, and pain points related to Abatatriptan. This will help inform marketing strategies and improve customer satisfaction.

**Factors Affecting Sales Growth and Loss:**
The following factors could impact sales growth and loss for Gleichner, Bahringer and Morar Pharmaceutical Limited:

* Changes in patient needs or disease prevalence
* Competitor activity or market share shifts
* Marketing efforts and promotional activities
* Regulatory changes or product labeling updates
* Economic conditions or reimbursement policies

These factors can influence demand, prices, and sales performance for Abatatriptan. By understanding these drivers, the company can develop strategies to mitigate risks and capitalize on opportunities.

**Conclusion:**
In conclusion, Gleichner, Bahringer and Morar Pharmaceutical Limited has a strong sales performance in 2-2017, with moderate sales growth and relatively low volatility. Pricing behavior appears normal, and there is an opportunity for further growth through targeted marketing efforts and sales optimization. By understanding the factors that drive sales growth and loss, the company can develop strategies to maintain its market position and achieve continued success."
